A new diagnosis of chronic lymphocytic leukemia (CLL) often comes with many unfamiliar medical terms. One of the first you may encounter is “treatment-naïve,” which simply means you have not yet received any treatment for CLL.
Do not be misled by the simplicity of the term, however; the choice made at this juncture carries more weight than one might think and will set the tone for how matters are handled should the disease make a return. Zanubrutinib is one of several treatment options discussed in early care planning. Here is a simplified summary of findings from clinical research.
The Meaning of Treatment-Naïve
CLL is not in a hurry. Many are diagnosed and carry on with their lives for a year or two, or far longer, before a physician deems it necessary to intervene. Until then, they are considered treatment-naïve.
There is a reason to make a distinction here. When a drug is put to the test in someone who has had no prior therapy, the results are unambiguous. There is no old chemo in the system and no cells that have become recalcitrant from previous courses of action. One can see the medicine’s true effect without anything else to obscure the view.
Inside the SEQUOIA Trial
Much of the clinical evidence supporting zanubrutinib in treatment-naïve chronic lymphocytic leukemia (CLL) comes from the Phase 3 SEQUOIA trial. This multicenter study enrolled patients with previously untreated CLL or small lymphocytic lymphoma (SLL) and evaluated zanubrutinib use across several study cohorts.
In the randomized cohort (Arm A), patients without del(17p) received either zanubrutinib or bendamustine plus rituximab (BR), which was a commonly used chemoimmunotherapy regimen at the time the study was designed.
A separate cohort (Arm B) enrolled patients with del(17p), a genetic abnormality associated with a poorer prognosis. This cohort evaluated the efficacy and safety of zanubrutinib in this higher-risk patient population.
What the Six-Year Numbers Actually Show
Here’s the part that stands out. After six years of watching these patients, Zanubrutinib continued to be evaluated for long-term outcomes in the study. About 12% of people on it saw their disease get worse. On the older combo, that number was around 41%. This represents a notable difference observed in the study results. Put in plain terms, Clinical trial results showed a reduction in the risk of progression or death compared to the comparator arm.
Response rates were strong too, sitting around 88%. And for a lot of these patients, that response was still holding years later when researchers came back to check. Researchers also reported findings in the del(17p) subgroup, though, was the del(17p) group. Outcomes in this subgroup were also evaluated within the study. Older treatments basically never managed that.
Adding Venetoclax to the Mix
In one part of the study, zanubrutinib was combined with venetoclax for a defined period rather than indefinitely. For those with high-risk TP53 mutations, the combination was effective in keeping 87 per cent of patients free from progression over a three-year span. Then there is the matter of mutation status; about 60 per cent of the cohort reached a stage where there was no measurable leukemia to be found in the blood.
It was not ideal, however. There’s nothing permanent in this world. This was the most common issue: a drop in some types of blood cells, so-called “neutropenia,” which translates into more blood tests and more infection monitoring during treatment.
What This Means For You (Or For Someone You Love)
If you’re indeed with a hematologist, pondering about what to do next, patients may discuss factors such as genetic markers and treatment duration preferences with their healthcare provider. Are you del(17p) or do you have a mutation of TP53? That’s all it takes to influence things one way or another. Would you prefer to take something for a specific amount of time or take the daily pill for the long-term? There is no right answer, and that’s okay. A good doctor will prefer to accompany you through it rather than a prescription one size fits all.
This article is intended for informational purposes only and should not be relied upon as a substitute for professional medical advice. Please consult a qualified healthcare professional for complete clinical information and guidance.
FAQs
Is zanubrutinib only for CLL?
Not quite. It has also been studied and approved for use in certain other B-cell malignancies, such as mantle cell lymphoma. But CLL and SLL are where most of the treatment-naïve research has focused so far.
How do people actually take it?
By mouth, usually once or twice a day, depending on what your doctor lays out for you.
Will being treatment-naïve affect what insurance covers?
It might. Coverage rules aren’t the same across the board, so a quick call to your insurer before starting can save you a headache down the line.
Do the side effects get easier over time?
For some people, yeah. Low white blood cell counts tend to show up earlier on and get managed through regular blood work and small dose changes when needed.